Opinion on R&D in United Kingdom

Select information type

Refine your search

search
Search tips

Published within

« | 1 | 2 | 3 | 4 | 5 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Xenova/QLT: tackling multidrug resistance

UK biotech Xenova and its North American ally QLT will trial tariquidar for multidrug resistance in non-small cell lung cancer. As long as the results are positive, tariquidar should have a bright future: multidrug resistance is an increasingly serious problem in cancer treatment, and the developers look set to provide strong marketing support.

Published By Datamonitor
11 Jul 2002
CommentWire
CommentWire

Women's health: more HPV risk than expected

In the new survey, featuring women in their first relationship, 74% of respondents reportedly used barrier contraception. Yet nearly half developed some form of HPV infection. Companies such as Merck and Origenix, with vaccines in development for the virus, are likely to see significant revenues when their products hit the market.

Published By Datamonitor
15 Feb 2002
Expert View
Expert View

Use of antibiotics to drop, but frustrated patients need to be better informed of the reasons

Independent market analyst Datamonitor's latest infectious diseases report, 'Respiratory Tract Infections' suggests that the way we use antibiotics may be about to change forever. Patients are increasingly going to find that they will not be prescribed antibiotics for some respiratory tract infections (RTIs), such as a sore throats, sinusitis, or bronchitis, as often as they used to be.

Published By Datamonitor
20 Feb 2002
Expert View
Expert View

UK Arthritis Sufferers Receiving Second Best in Pain Medication

Many rheumatoid and osteoarthritis sufferers in the UK may have to settle for second best in pain medication and are being put at risk of developing serious gastrointestinal side effects (GI) according to market analysts, Datamonitor.

Published By Datamonitor
20 Feb 2002
CommentWire
CommentWire

Tuberculosis: governments need to take action

If a TB epidemic were to occur, the impact could far outweigh the risks more publicized infections such as HIV and meningitis. The current treatments could leave many patients uncured, and there is little in the pipeline to replace them. Governments should consider subsidizing research into more effective drugs, or risk facing the consequences.

Published By Datamonitor
26 Mar 2002
ResearchWire
ResearchWire

Stroke: 7% of UK patients present within necessary time window

Published By Datamonitor
09 Jul 2001
CommentWire
CommentWire

Stem cell research: Europe seizes the advantage

The House of Lords committee was set up to review the ethical implications of allowing human embryonic cloning for research into degenerative diseases. Despite fierce campaigning by 'pro-life' groups, it came out in favor. Particularly after the recent restrictions imposed in the US, a 'reverse brain drain' of investment from the US to Europe could be on the cards.

Published By Datamonitor
28 Feb 2002
CommentWire
CommentWire

Shire: merger paying off, despite pipeline problems

Published By Datamonitor
24 Jul 2001
Expert View
Expert View

Pharmaceutical Licensing Weekly Review: August 19 - 23, 2002

Last week's licensing news featured three of the world's biggest pharmaceutical companies: first GlaxoSmithKline joined Pfizer in an alliance with Argonaut, then Pharmacia joined forces with BattellePharma. Johns Hopkins University also had a busy week beating out deals with Crucell and Correlogic Systems. Finally Amgen and Praecis agreed to terminate their failed relationship.

Published By Datamonitor
23 Aug 2002
CommentWire
CommentWire

Oxford GlycoSciences: Vevesca paves the way

Published By Datamonitor
26 Sep 2001

« | 1 | 2 | 3 | 4 | 5 | » »|

No help is available.